Any N-acylamino acid having L-configuration.
ChEBI ID: 21644
Member | Definition | Role |
---|---|---|
(2S)-3-(1H-indol-3-yl)-2-[[2-[(4-methyl-6-oxo-3-benzo[c][1]benzopyranyl)oxy]-1-oxoethyl]amino]propanoic acid | (2S)-3-(1H-indol-3-yl)-2-[[2-[(4-methyl-6-oxo-3-benzo[c][1]benzopyranyl)oxy]-1-oxoethyl]amino]propanoic acid | |
n-acetyl-s-(2-cyanoethyl)cysteine | N-Acetyl-S-(2-cyanoethyl)-cysteine | |
n-acetyl-s-(propionamide)cysteine | N-Acetyl-S-(2-carbamoylethyl)-cysteine | |
n-acetyl-s-allylcysteine | N-acetyl-S-allylcysteine | |
s-(3-hydroxypropyl)cysteine n-acetate | N-Acetyl-S- (3-hydroxypropyl)-cysteine | |
s-trichlorovinyl-n-acetylcysteine | N-Acetyl-S-(trichlorovinyl)-cysteine | |
zofenopril | A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat. | zofenopril |
zofenoprilate | A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-2-methyl-3-sulfanylpropanoyl group. The active metabolite of zofenopril. | zofenoprilat |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 19 (8.02) | 18.7374 |
1990's | 52 (21.94) | 18.2507 |
2000's | 55 (23.21) | 29.6817 |
2010's | 92 (38.82) | 24.3611 |
2020's | 19 (8.02) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 42 (16.34%) | 5.53% |
Reviews | 26 (10.12%) | 6.00% |
Case Studies | 1 (0.39%) | 4.05% |
Observational | 2 (0.78%) | 0.25% |
Other | 186 (72.37%) | 84.16% |